ArticleTherapeutic advances in medical oncology2013
Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?
Article in Therapeutic advances in medical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Early-like differentiation status of systemic PD-1Clinical & translational immunology · 2022Article
- Pyroptosis-Related LncRNA Signatures Correlate With Lung Adenocarcinoma Prognosis.Frontiers in oncology · 2022Article
- Long noncoding RNA SNHG20 regulates cell migration, invasion, and proliferation via the microRNA-19b-3p/RAB14 axis in oral squamous cell carcinoma.Bioengineered · 2021Article
- Isolation and Purification of a New Bacillus Subtilis Strain from Deer Dung with Anti-microbial and Anti-cancer Activities.Current medical science · 2021Article
- INSL4 as prognostic marker for proliferation and invasiveness in Non-Small-Cell Lung Cancer.Journal of Cancer · 2021Article
- Artificial Intelligence Tools for Refining Lung Cancer Screening.Journal of clinical medicine · 2020Review
- Review
- Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis.BMC cancer · 2020Article
- LncRNA MALAT1 Aggravates the Progression of Non-Small Cell Lung Cancer by Stimulating the Expression of COMMD8 via Targeting miR-613.Cancer management and research · 2020Article
- A Potent Autophagy Inhibitor (Lys05) Enhances the Impact of Ionizing Radiation on Human Lung Cancer Cells H1299.International journal of molecular sciences · 2019Article
- Cooperative adaptation to therapy (CAT) confers resistance in heterogeneous non-small cell lung cancer.PLoS computational biology · 2019Article
- LncRNA TP73-AS1 promoted the progression of lung adenocarcinoma via PI3K/AKT pathway.Bioscience reports · 2019Article
- Article
- The Daniel K. Inouye College of Pharmacy Scripts: Targeted Nanocarrier Based Systems for the Treatment of Lung Cancer.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2017Review
- tRF-Leu-CAG promotes cell proliferation and cell cycle in non-small cell lung cancer.Chemical biology & drug design · 2017Article
- Gene Expression Signature Differentiates Histology But Not Progression Status of Early-Stage NSCLC.Translational oncology · 2017Article
- Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer.Lung cancer (Amsterdam, Netherlands) · 2017Article
- TRAIL-functionalized gold nanoparticles selectively trigger apoptosis in polarized macrophages.Nanotheranostics · 2017Article
- ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma.Scientific reports · 2016Article
- Functional role of eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) in NSCLC.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The search for innovative therapeutic agents in non-small cell lung cancer (NSCLC) has witnessed a swift evolution. The number of targeted drugs that can improve patient outcomes with an acceptable safety profile is steadily increasing. In this review, we highlight current drugs that have already been approved or are under evaluation for the treatment of patients with NSCLC, either in monotherapy or combined therapy for both the first- and second-line settings. Experience with drugs targeting the vascular endothelial growth factor and its receptor, as well as the epidermal growth factor receptor is summarized. Moreover, we provide an overview of more novel targets in NSCLC and initial experience with the respective therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.